Enterprise Storage Forum
In another SSD news, STEC (NASDAQ: STEC) shares fell 10 percent in after-hours trading tonight after the enterprise SSD market leader's quarterly results beat ...
and more »
Welcome to my new trading blog based of after hours stocks. Please subscribe for updates.
CIT Group Inc. (NYSE: CIT) has seen its shares halted for news pending, and then they reopened higher after it has amended its pending tender offer for its $1 billion of Floating Rate Senior Notes due August 17, 2009. Notes under the new amended tender will receive the amended purchase price of $875 in change per $1,000 principal turn of notes kinda than the prior $825 per $1,000 principal turn of notes. CIT stock is today up 15% at $1.00 and its 52 meg share average regular intensity has just been hit on brawny block volume. Roughly half of that intensity has come since shares were re-opened for trading. -Jon C. Ogg
Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) is up huge after the company announced an commendation with the bureau on a Special Protocol Assessment for its Phase 3 Trial of KRX-0401 in the treatment of multiple myeloma. KERX is up almost 50% from this morning’s programme and we hit seen almost 9.9 million shares change hands as of 10:38 AM ESt. This trades an cipher of about 2.2 million shares and its 52-week arrange is $0.09 to $1.88.
This programme also has partner Aeterna Zentaris Inc. (NASDAQ: AEZS) trading up nearly 7% at $2.80 on 490,000 shares. Its 52-week arrange is $0.26 to $3.25 and cipher intensity is 235,000 shares.
Jon C. Ogg
August 3, 2009 (10:38 AM EST)
Oncothyreon Inc. (NASDAQ: ONTY) is a rare stock for volume alerts. It showed clinical data relating to long-term communication with Stimuvax were presented at the International Association for the Study of Lung Cancer’s 13th World Conference on Lung Cancer in San Francisco over the weekend. As of April 2009, 10 of the 16 unnatural patients were alive without grounds of disease progression and eight continued to obtain therapy with Stimuvax after 6.3 to 8.2 years. The remaining two experience patients discontinued Stimuvax therapy after 2.4 and 5.8 years and were without grounds of disease progression. Nine of the 10 experience patients had stage IIIb NSCLC upon entry to the trial, while digit had stage IV disease. Six of the 10 experience patients had a complete salutation to their first-line chemotherapy or chemo-radiation, while four patients had stable disease. The remaining six of the 16 patients discontinued Stimuvax after 2.0 to 5.1 years of communication as a result of disease progression and are deceased. A 8:23 AM EST we have seen nearly 100,000 shares trade hands versus an cipher daily volume of wrinkled 400,000 shares per day. Shares are up 13% at $5.25 after closing at $4.629 on Friday. -JON OGG